PMID- 27778459
OWN - NLM
STAT- MEDLINE
DCOM- 20190409
LR  - 20190409
IS  - 1756-185X (Electronic)
IS  - 1756-1841 (Linking)
VI  - 21
IP  - 10
DP  - 2018 Oct
TI  - Infliximab equivalently suppresses oxidative stress compared to tocilizumab among 
      well-controlled patients with rheumatoid arthritis.
PG  - 1815-1821
LID - 10.1111/1756-185X.12972 [doi]
AB  - AIM: This study was designed to investigate which biological agent, infliximab or 
      tocilizumab, would more intensively keep suppressing oxidative stress among 
      well-controlled patients as C-reactive protein (CRP) levels normalized in 
      rheumatoid arthritis (RA). In addition, it was intended to clarify indicative 
      factors of oxidative stress among well-controlled patients with RA. METHODS: We 
      recruited 61 well-controlled (CRP < 0.3 mg/dL within normal ranges) patients with 
      RA using biological agents (infliximab n = 33; tocilizumab n = 28), active RA 
      patients with CRP > 1.0 mg/dL (n = 10) and healthy subjects (n = 10) and examined 
      the fraction of oxidized albumin (oxidized-albumin [%]) as a marker of oxidative 
      stress in addition to inflammatory measures and disease activity scores such as 
      CRP, erythrocyte sedimentation rate (ESR), matrix metalloproteinase 3 (MMP-3), 
      serum amyloid A (SAA), Clinical Disease Activity Index, Simplified Disease 
      Activity Index, visual analog scale (VAS), Disease Activity Index of 28 joints 
      (DAS28)-CRP, DAS28-ESR and renal function (creatinine clearance [CCr]). RESULTS: 
      Oxidized-albumin (%) was significantly elevated among active RA patients (33.83 +/- 
      5.31%) as compared with healthy subjects (23.00 +/- 2.56%). Although 
      oxidized-albumin (%) among well-controlled RA patients also increased, there was 
      no difference with oxidized-albumin (%) between infliximab and tocilizumab groups 
      (26.40 +/- 5.44% in infliximab; 26.62 +/- 4.53% in tocilizumab). In Pearson's 
      correlation, oxidized-albumin (%) had significant correlations with CRP, MMP-3, 
      ESR, SAA, age, CCr, VAS, DAS28-CRP and DAS28-ESR. With those variables, multiple 
      stepwise forward regression analysis was conducted and revealed that CCr, 
      DAS28-ESR and CRP are the statistically significant explanatory variables on 
      oxidized-albumin (%) among well-controlled RA patients. CONCLUSIONS: We 
      demonstrated that there was no difference with infliximab and tocilizumab on 
      oxidative stress and we clarified that CCr, DAS28-ESR and CRP become indicative 
      factors of oxidative stress among well-controlled RA patients.
CI  - (c) 2016 Asia Pacific League of Associations for Rheumatology and John Wiley & Sons 
      Australia, Ltd.
FAU - Kizaki, Kazuha
AU  - Kizaki K
AD  - Department of Orthopaedic Surgery and Rheumatology, Kyoto Shimogamo Hospital, 
      Kyoto, Japan.
FAU - Yamashita, Fumiharu
AU  - Yamashita F
AD  - Department of Orthopaedic Surgery and Rheumatology, Kyoto Shimogamo Hospital, 
      Kyoto, Japan.
FAU - Hayashi, Tomoya
AU  - Hayashi T
AD  - Department of Sports Science, Meiji University of Integrative Medicine, Kyoto, 
      Japan.
FAU - Funakoshi, Noboru
AU  - Funakoshi N
AD  - Department of Orthopaedic Surgery and Rheumatology, Kyoto Shimogamo Hospital, 
      Kyoto, Japan.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
DEP - 20161024
PL  - England
TA  - Int J Rheum Dis
JT  - International journal of rheumatic diseases
JID - 101474930
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antioxidants)
RN  - 0 (Antirheumatic Agents)
RN  - 0 (Biomarkers)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Serum Amyloid A Protein)
RN  - 9007-41-4 (C-Reactive Protein)
RN  - B72HH48FLU (Infliximab)
RN  - EC 3.4.24.17 (MMP3 protein, human)
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
RN  - I031V2H011 (tocilizumab)
RN  - ZIF514RVZR (Serum Albumin, Human)
SB  - IM
MH  - Aged
MH  - Antibodies, Monoclonal, Humanized/adverse effects/*therapeutic use
MH  - Antioxidants/adverse effects/*therapeutic use
MH  - Antirheumatic Agents/adverse effects/*therapeutic use
MH  - Arthritis, Rheumatoid/blood/diagnosis/*drug therapy
MH  - Biomarkers/blood
MH  - Blood Sedimentation
MH  - C-Reactive Protein/metabolism
MH  - Case-Control Studies
MH  - Female
MH  - Humans
MH  - Inflammation Mediators/blood
MH  - Infliximab/adverse effects/*therapeutic use
MH  - Male
MH  - Matrix Metalloproteinase 3/blood
MH  - Middle Aged
MH  - Oxidation-Reduction
MH  - Oxidative Stress/*drug effects
MH  - Serum Albumin, Human/metabolism
MH  - Serum Amyloid A Protein/metabolism
MH  - Time Factors
MH  - Treatment Outcome
OTO - NOTNLM
OT  - albumin
OT  - infliximab
OT  - rheumatoid arthritis
OT  - tocilizumab
EDAT- 2016/10/26 06:00
MHDA- 2019/04/10 06:00
CRDT- 2016/10/26 06:00
PHST- 2016/10/26 06:00 [pubmed]
PHST- 2019/04/10 06:00 [medline]
PHST- 2016/10/26 06:00 [entrez]
AID - 10.1111/1756-185X.12972 [doi]
PST - ppublish
SO  - Int J Rheum Dis. 2018 Oct;21(10):1815-1821. doi: 10.1111/1756-185X.12972. Epub 
      2016 Oct 24.